NWNele Wellinghausen

Nele Wellinghausen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nele Wellinghausen has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Upsurge of Chlamydia pneumoniae respiratory tract infections in 2024/2025 in Southern Germany

    by Nele Wellinghausen, Susanne Deininger, Reinhard Frodl, Meike Voss, Lisa Wischmann, Dietmar Plonné

    We report a never seen before upsurge of Chlamydia pneumoniae (Cp) respiratory tract infections in 2024/25 in southern Germany. Regarding 43,558 Cp PCR tests analyzed, the positivity rate increased from 0.3% in 2015–2020 to 2.6% in 2024, and 2.4% in 2025 until August 2025, peaking at ≥ 6.0% with > 100 monthly cases in October and November 2024. Children aged 6–14 years were predominantly affected, and co-infections with other pathogens were frequently detected. We aim at raising awareness concerning Cp infections.


  • Rationale Infektionsdiagnostik in der Pädiatrie

    by Nele Wellinghausen, Fabian Lander

    Infektionen sind ein häufiger Grund für eine Vorstellung in der kinderärztlichen Praxis. Wenn klinische Untersuchung und Anamnese nicht für die Diagnosestellung ausreichen, können Laboruntersuchungen helfen. In diesem Artikel wird eine rationale Infektionsdiagnostik vorgestellt, die das jeweilige Krankheitsbild, spezielle Risikofaktoren und aktuelle Epidemiologie berücksichtigt. Zusätzlich werden typische Fallstricke bei der Interpretation der Befunde aufgezeigt. Article published online: 30 May 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Rationale Infektionsdiagnostik in der Pädiatrie

    by Nele Wellinghausen, Fabian Lander

    Infektionen sind ein häufiger Grund für eine Vorstellung in der kinderärztlichen Praxis. Wenn klinische Untersuchung und Anamnese nicht für die Diagnosestellung ausreichen, können Laboruntersuchungen helfen. In diesem Artikel wird eine rationale Infektionsdiagnostik vorgestellt, die das jeweilige Krankheitsbild, spezielle Risikofaktoren und aktuelle Epidemiologie berücksichtigt. Zusätzlich werden typische Fallstricke bei der Interpretation der Befunde aufgezeigt. Article published online: 23 May 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    Evaluation of a Treponema IgG ELISA alone and in combination with an IgM ELISA as substitutes for Treponema pallidum particle agglutination (TPPA) as confirmatory tests in a two-tier diagnostic algorithm for diagnosis of syphilis infection

    by Nele Wellinghausen, Teresa Esthela Rangel Vivar, Dietmar Plonné

    Objectives: The Treponema pallidum particle agglutination (TPPA) has been used for decades for serological diagnostics of syphilis but is no longer available. Therefore, we evaluated the Treponema IgG ELISA (TpG) alone and in combination with the Treponema IgM ELISA (TpG+M, both from Euroimmun) as possible substitutes for TPPA as a confirmatory test in a two-tier syphilis screening algorithm. Furthermore, we investigated whether a TPPA titer of 5,120 which is used as cut-off for therapeutic decision in pregnant women in Germany can be transferred to an appropriate cut-off value of the TpG. Methods: All serum samples with reactive syphilis screening test (CLIA, Diasorin) within a 13-months period were included (n=739). In addition to TPPA and rapid plasma reagin test both ELISA tests were done in all samples. Results: Sensitivity, specificity, positive and negative predictive values were 92.2, 100, 100, and 74.5 % for TpG, and 93.2, 85.4, 96.6, and 74.1 % for TpG+M. By ROC analysis the cut-off of TpG corresponding to a TPPA titer ≥5,120 was calculated to be 54 RU/mL with a sensitivity of 99.6 % and a resulting specificity of 58.6 %. Conclusions: TpG appears suitable to substitute TPPA as a confirmatory test for syphilis diagnostics but TpG-negative samples have to be evaluated by further tests like FTA-Abs or immunoblot. Treponema IgM determined in addition to TpG did not improve the test performance compared to the TPPA as a reference standard. Valid prediction of a TPPA titer ≥5,120 from TpG result appears not reasonable.

  • Open Access

    Comparison of Treponema-specific immunoglobulin G (IgG) index with Treponema pallidum particle agglutination (TPPA) index for detection of intrathecal Treponema-specific antibody synthesis for serological diagnosis of neurosyphilis.

    by Nele Wellinghausen, Andrea Götz, Teresa Esthela Rangel Vivar

    The determination of Treponema-specific intrathecal immunoglobulin synthesis with the Treponema pallidum particle agglutination (TPPA) index is a well-established method recommended in German guidelines for the diagnosis of neurosyphilis. However, the TPPA test is no longer available. The aim of this study was to evaluate whether the determination of a Treponema-specific immunoglobulin G (IgG) index can substitute the TPPA index. Serum and cerebrospinal fluid (CSF) samples from patients with confirmed (n=6) and probable (n=3) neurosyphilis as well as patients with adequately treated syphilis without neurosyphilis (n=4) were investigated. In addition to index calculation further CSF parameters were determined. The results of the Treponema IgG and the TPPA index were consistent in all patients with confirmed neurosyphilis and non-neurosyphilis patients. In two patients with probable neurosyphilis the IgG index appeared more plausible than the TPPA index when taking into account all available laboratory and clinical data of the patients. In conclusion, the determination of Treponema-specific intrathecal immunoglobulin synthesis with the IgG index appears to be a suitable alternative to the TPPA index.

  • Open Access

    A family cluster of schistosomiasis acquired in Solenzara River, Corsica (France) — Solenzara River is clearly a transmission site for schistosomiasis in Corsica

    by Nele Wellinghausen, Hélène Moné, Gabriel Mouahid, Axel Nebel, Dennis Tappe, Martin Gabriel

    We report a patient with urogenital schistosomiasis and three cases of subclinical infection within one family acquired from Solenzara River, Corsica, in 2019. Our cases confirm that transmission of schistosomiasis in Corsica is ongoing and has been extended from the Cavu River to the Solenzara River. Solenzara River is clearly a transmission site for schistosomiasis in Corsica. Public health efforts are recommended to uncover and prevent further cases.


  • Open Access

    Comparative study of a new commercial recombinant line assay and two immunoassays for detection of SARS-CoV-2 IgG antibodies in PCR-confirmed outpatients

    by Nele Wellinghausen, Ralitsa Ivanova, Susanne Deininger, Andrea Götz

    Objectives: Commercially available immunoassays have been developed for detection of antibodies against SARS-CoV-2. However, equivocal and discrepant results between different immunoassay can occur requiring further assessment by confirmatory tests. Methods: We investigated the new commercial line assay recomLine SARS-CoV-2 IgG (Mikrogen, containing the antigens S1, receptor-binding domain of the spike protein, and nucleocapsid protein (NP) of SARS-CoV-2) within a collection of well characterized serum samples from COVID-19 outpatients (n=49) and SARS-CoV-2-PCR-positive asymptomatic contact persons (n=6) in comparison to two commercial immunoassays, the S1 antigen based Anti-SARS-CoV-2-ELISA IgG by Euroimmun and the NP based Elecsys® Anti-SARS-CoV-2 by Roche. Results: The recomLine assay was positive in all samples which had an equivocal or positive result for SARS-CoV-2 antibodies in at least one of the two immunoassays. It showed high agreement with the overall results of the immunoassays (94.5% [Cohen’s kappa = 0.85] and 92.7% [Cohen’s kappa 0.81] to the ELISA by Euroimmun and the assay by Roche, respectively). In addition, high agreement of the reactivity to the specific antigens S1 and NP in the recomLine assays compared to the results of the S1 based ELISA and NP based Elecsys® assay, was found (90.9% [Cohen’s kappa 0.78] and 96.4% [Cohen’s kappa 0.91] for S1 and NP, respectively). Conclusions: The new recomLine SARS-CoV-2 IgG assay may be used as an additional tool for investigation of equivocal or discrepant results of Anti-SARS-CoV-2 immunoassays and for antigen-specific detection of SARS-CoV-2 IgG antibodies.

    • 16 September 2020
      • Vol. 8
    Open Access

    Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays

    by Nele Wellinghausen, Meike Voss, Ralitsa Ivanova, Susanne Deininger

    Commercially available immunoassays have been developed for sensitive and specific detection of antibodies against SARS-CoV-2. While high sensitivity has been reported in hospitalized COVID-19 patients, little is known about the performance of the assays in ambulatory patients. Therefore, we evaluated the SARS-CoV-2-IgG response in 51 SASR-CoV-2-PCR-confirmed outpatients with five commercial immunoassays. The sensitivity in serum samples, collected at a median of 24 days after onset of symptoms, detected by the Anti-SARS-CoV-2-ELISA IgG (Euroimmun), EDI™ Novel Coronavirus COVID-19 IgG ELISA (Epitope Diagnostics), Liaison® SARS-CoV-2 S1/S2 IgG (Diasorin), SARS-CoV-2 IgG on the Architect™ i2000 (Abbott), and Elecsys® Anti-SARS-CoV-2 (IgM/IgA/IgG) on the cobas™ e801 (Roche) was 84.3%, 78.4%, 74.5%, 86.3%, and 88.2%, respectively. The sensitivity in serum samples, collected >20 days after onset of symptoms, varied between 75.0% and 90.0%, and in samples, collected at least 28 days after onset of symptoms, did not increase, except in the Anti-SARS-CoV-2-ELISA IgG by Euroimmun (90.0%). There was not an obvious association between the type of the antigen (N versus S protein) and the overall sensitivity of the assays. Our results show significant individual differences of the IgG response against SARS-CoV-2, additionally confirmed in three patients with follow-up serum samples and seven asymptomatic but PCR-positive contact persons. In conclusion, our study shows that commercially available immunoassays detect SARS-CoV-2-IgG or total antibodies in outpatients with a satisfying sensitivity, but lower than that reported for hospitalized patients. In asymptomatic persons the SARS-CoV-2-IgG response may even be absent in a relevant percentage of persons.


  • Open Access

    SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons

    by Nele Wellinghausen, Dietmar Plonné, Meike Voss, Ralitsa Ivanova, Reinhard Frodl, Susanne Deininger


  • Occurrence of Immunoglobulin M Antibodies against Several Bacterial and Viral Pathogens in Acute Hantavirus Infection

    by Nele Wellinghausen, Andrea Goetz, Ursula Weber

    Elevated levels of immunoglobulin M antibodies against various pathogens, most frequently Epstein-Barr-virus and Coxiella burnetii , were detected by immunoassay in 15 of 48 patients (31.3%) with acute Puumala virus infections. Although the mechanisms leading to this IgM response are not clear yet, polyspecific immunoglobulin M antibodies have to be taken into account to avoid misinterpretation of serological results in acute hantavirus infection.